Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

Unlike biologics, nonbiologic systemic therapies showed a neutral or slightly increased cardiovascular risk, raising concerns about their long-term safety.

Reduced Cardiovascular Risk with Biologics in Psoriasis and PsA  

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Jiyeon Oh’s research confirms that a personalized approach is needed to treat all complexities associated with AD.

Why Atopic Dermatitis Treatment is Not “One Size Fits All,” According to Jiyeon Oh

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Researchers reported the case of a 28-year-old woman with epidermodysplasia verruciformis who developed SCC on a sun-protected scalp.

Researchers Report Rare Case of Squamous Cell Carcinoma in Sun-Shielded Area in Epidermodysplasia Verruciformis

The study stated early recognition and aggressive treatment of childhood-onset MMP are essential to prevent permanent scarring.

Multicenter Study Sheds Light on Pediatric MMP

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Journal

Dermatology Times, Real-World Approaches to Nonsteroidal and Systemic Atopic Dermatitis Treatment, March 2025 (Vol. 46. Supp. 02)

At a recent Dermatology Times Case-Based Roundtable event, James Q. Del Rosso, DO, discussed the limitations of topical corticosteroids and the benefits of nonsteroidals.

Case-Based Insights on Ruxolitinib vs Corticosteroids for Atopic Dermatitis

Nonsteroidal AD therapies are gaining attention due to their rapid effectiveness and ability to offer an alternative to long-term steroid use.

A Case-Based Approach to Topical and Nonsteroidal AD Management

Nonsteroidal Approaches to Chronic and Severe Atopic Dermatitis